AGC
AEON icon

Angelo Gordon & Co’s AEON Biopharma AEON Stock Holding History

Angelo Gordon & Co’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-347
Closed -$251K – 116
2022
Q4 		$251K Hold
347
– – 0.05% 145
2022
Q3 		$246K Buy
+347
New +$246K 0.04% 216

Other funds holding AEON

SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
CCA
Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
GCWM
Graham Capital Wealth Management Washington D.c., District of Columbia $113M AUM 11.26% 1-Year Est. Return

Angelo Gordon & Co's AEON Position: Q1 2023 in Review

Angelo Gordon & Co sold out of AEON Biopharma (AEON) in Q1 2023, closing a stake of 347 shares — an estimated $251K sold.

Angelo Gordon & Co first reported a position in AEON in Q3 2022 and held it in 2 quarters. The position peaked at $251K in Q4 2022. 21 funds tracked by Wall St. Rank hold AEON as of Q1 2023.

  • Angelo Gordon & Co reported no remaining AEON Biopharma position as of Q1 2023 after selling out during the quarter.
  • Angelo Gordon & Co sold 347 AEON Biopharma shares in Q1 2023, an estimated $251K.
  • Angelo Gordon & Co first reported a position in AEON Biopharma in Q3 2022 and held it in 2 quarters.
  • Angelo Gordon & Co's AEON Biopharma position peaked at $251K in Q4 2022.
  • 21 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2023.

Based on Angelo Gordon & Co's 13F filing for Q1 2023, filed 15 May 2023.